Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press32510.17650/1726-9776-2010-6-4-16-22DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиSEQUENTIAL USE OF TARGET AGENTS AND THEIR COMBINATION IN THE TREATMENT FOR METASTATIC RENAL CELL CARCINOMAПРИМЕНЕНИЕ ТАРГЕТНЫХ ПРЕПАРАТОВ В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ: ПОСЛЕДОВАТЕЛЬНОЕ НАЗНАЧЕНИЕ ИЛИ КОМБИНАЦИЯAlekseyevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruKalpinskyA. S.КалпинскийА. С.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Research Oncological Institute, Russian Agency for Medical TechnologiesМНИОИ им. П.А. Герцена Росмедтехнологий301220106416220608201406082014https://oncourology.abvpress.ru/oncur/article/view/325

The development of molecular biology led to the discovery of major pathogenetic pathways in the development of renal cell carcinoma (RCC), contributing to the designing of novel drugs to treat metastatic RCC, which belong to a group of target agents or tyrosine kinase inhibitors. Phases II and III clinical trials have proven the efficacy and controlled safety profile of a broad range of drugs for the treatment of metastatic RCC. The developing resistance to drugs and their intolerance determine the need to conduct new clinical studies and to search for novel agents and treatment regimens to improve survival and quality of life in patients. The performed studies of the efficiency and safety of sequential use of antiangiogenic drugs and their combination have supported that it is expedient to apply these treatment policies to patients with metastatic RCC. The expected results from the ongoing large Phase III clinical trials will let one find out how to optimally use target agents, in what combination or in what sequence.

Достижения молекулярной биологии позволили выяснить основные патогенетические пути развития почечно-клеточного рака (ПКР), что способствовало созданию новых препаратов для лечения метастатического ПКР, относящихся к группе таргетных препаратов или ингибиторов тирозинкиназы. В клинических исследованиях II и III фазы доказаны эффективность и управляемый профиль безопасности широкого спектра препаратов для лечения метастатического ПКР. Развивающаяся резистентность и непереносимость препаратов обусловливают необходимость в проведении новых клинических исследований, поиска новых препаратов и схем лечения, направленных на улучшение показателей выживаемости и качества жизни больных. Проведенные исследования по изучению эффективности и безопасности последовательного применения антиангиогенных препаратов и их комбинации подтвердили целесообразность использования этих стратегий лечения у больных метастатическим ПКР. Ожидаемые результаты продолжающихся крупных клинических исследований III фазы позволят выяснить, как оптимально использовать таргетные препараты, в какой комбинации или последовательности.

metastatic renal cell carcinomatarget therapytyrosine kinase inhibitorsметастатический почечно-клеточный рактаргетная терапияингибиторы тирозинкиназы1. Cohen H., McGovern F. Renal Cell carcinoma. N Engl J Med 2005;353:3477–90.Cohen H., McGovern F. Renal Cell carcinoma. N Engl J Med 2005;353:3477–90.2. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 году. М., 2010.Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2008 году. М., 2010.3. Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82–7.Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82–7.4. Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell arcinoma. Eur Urol 2008;54, issue 2:315–25.Ravaud A., Wallerand H., Culine S. et al. Update on the medical treatment of metastatic renal cell arcinoma. Eur Urol 2008;54, issue 2:315–25.5. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–45.Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–45.6. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109–14.Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109–14.7. Ljungberg B., Cowan N., Hanbury D.C. et al. Guidelines on renal cell carcinoma. European Association of Urology Web site. http://www.uroweb.org Доступно в сети Интернет с апреля 2010 г.Ljungberg B., Cowan N., Hanbury D.C. et al. Guidelines on renal cell carcinoma. European Association of Urology Web site. http://www.uroweb.org Доступно в сети Интернет с апреля 2010 г.8. NCCN clinical practice guidelines in oncology: kidney cancer (V.2.2010). National Comprehensive Cancer Network Web site. http://www.nccn.org. Доступно в сети Интернет.NCCN clinical practice guidelines in oncology: kidney cancer (V.2.2010). National Comprehensive Cancer Network Web site. http://www.nccn.org. Доступно в сети Интернет.9. Bracarda S., De Simone V. Sequential therapies in metastatic renal cell carcinoma:option or strategy? Eur Urol 2008; 54:1219–22.Bracarda S., De Simone V. Sequential therapies in metastatic renal cell carcinoma:option or strategy? Eur Urol 2008; 54:1219–22.10. Bellmunt J. Future developments in renal cell carcinoma. Ann Onc 2009;20:i13–17.Bellmunt J. Future developments in renal cell carcinoma. Ann Onc 2009;20:i13–17.11. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.12. Tamaskar I., Garcia J.A., Elson P. et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81–6.Tamaskar I., Garcia J.A., Elson P. et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81–6.13. Shepard D.R., Rini B.I., Garcia J.A. et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26 (20 suppl);abstr 5123.Shepard D.R., Rini B.I., Garcia J.A. et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26 (20 suppl);abstr 5123.14. Rini B.I., Michaelson M.D.,Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743–8.Rini B.I., Michaelson M.D.,Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743–8.15. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56.16. Escudier B., Ravaud A., Oudard S. et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [abstract 720]. Ann Oncol 2008;19:viii45.Escudier B., Ravaud A., Oudard S. et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [abstract 720]. Ann Oncol 2008;19:viii45.17. Motzer R., Kay A., Figlin R. et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [abstract 278]. American Society of Clinical Oncology Web site. http://www.asco.org. Доступно в сетиMotzer R., Kay A., Figlin R. et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [abstract 278]. American Society of Clinical Oncology Web site. http://www.asco.org. Доступно в сетиИнтернет с июня 2009 г.18. Dutcher J.P., Wild D., Hudes G.R. et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 2008;26(20 Suppl);abstr 5127.Dutcher J.P., Wild D., Hudes G.R. et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J Clin Oncol 2008;26(20 Suppl);abstr 5127.19. Rini B.I., Wilding G., Hudes G. et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(27):4462–8.Rini B.I., Wilding G., Hudes G. et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27(27):4462–8.20. Sablin M., Bouaita L., Balleyguier C. et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007 (20 Suppl);abstr 5038.Sablin M., Bouaita L., Balleyguier C. et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007 (20 Suppl);abstr 5038.21. Escudier B., Goupil M.G., Massard C. et al. Sequential therapy in renal cell carcinoma. Cancer 2009; 115(10 suppl):2321–6. 22. www.clinicaltrials.gov. Доступно в сети Интернет.Escudier B., Goupil M.G., Massard C. et al. Sequential therapy in renal cell carcinoma. Cancer 2009; 115(10 suppl):2321–6. 22. www.clinicaltrials.gov. Доступно в сети Интернет.23. Sosman J., Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009;115(10 Suppl):2368–75.Sosman J., Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009;115(10 Suppl):2368–75.24. Sternberg C.N., Bellmunt J., Grunwald V. et al. Advances in the management of metastatic renal cell cancer. Eur Urol Suppl 2009;8:758–61.Sternberg C.N., Bellmunt J., Grunwald V. et al. Advances in the management of metastatic renal cell cancer. Eur Urol Suppl 2009;8:758–61.25. Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889–96.Hainsworth J.D., Sosman J.A., Spigel D.R. et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889–96.26. Hainsworth J.D., Spigel D.R., Sosman J.A. et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 2007;5:427–32.Hainsworth J.D., Spigel D.R., Sosman J.A. et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 2007;5:427–32.27. Bukowski R.M., Kabbinavar F.F., Figlin R.A. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536–41.Bukowski R.M., Kabbinavar F.F., Figlin R.A. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536–41.28. Sosman J.A., Flaherty K.T., Atkins M.B et al. Updated results of phase I trial of sorafenib (S) and evacizumab (B) in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 5011.Sosman J.A., Flaherty K.T., Atkins M.B et al. Updated results of phase I trial of sorafenib (S) and evacizumab (B) in patients with metastatic renal cell cancer (mRCC) [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 5011.29. Whorf R.C., Hainsworth J.D., Spigel D.R. et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 5010.Whorf R.C., Hainsworth J.D., Spigel D.R. et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 5010.30. Merchan J.R., Liu G., Fitch T. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract]. J Clin Oncol 2007;25(18S); abstr 5034.Merchan J.R., Liu G., Fitch T. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract]. J Clin Oncol 2007;25(18S); abstr 5034.31. Feldman D.R., Ginsberg M.S., Baum M. et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2008;26(20 suppl);abstr 5100.Feldman D.R., Ginsberg M.S., Baum M. et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma [abstract]. J Clin Oncol 2008;26(20 suppl);abstr 5100.32. Cooney M.M., Garcia J.A., Elson P. et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 3530.Cooney M.M., Garcia J.A., Elson P. et al. Sunitinib and bevacizumab in advanced solid tumors: a phase I trial [abstract]. J Clin Oncol 2008;26(20 Suppl);abstr 3530.33. Feldman D.R., Baum Michael S., Ginsberg Michelle S. et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432–9.Feldman D.R., Baum Michael S., Ginsberg Michelle S. et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432–9.34. Fischer P., Patel P., Carducci M.A. et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma [abstr.]. J Clin Oncol 2008;26(20 suppl);abstr 16020.Fischer P., Patel P., Carducci M.A. et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma [abstr.]. J Clin Oncol 2008;26(20 suppl);abstr 16020.35. Hainsworth J.D., Spigel D.R., Burris H.A. et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28(13):2131–6.Hainsworth J.D., Spigel D.R., Burris H.A. et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010;28(13):2131–6.36. Escudier B.J., Negrier S., Gravis G. et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 2010;28(15 Suppl):4516.Escudier B.J., Negrier S., Gravis G. et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 2010;28(15 Suppl):4516.